I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors has authorized a stock repurchase program under
Mylan and Fujifilm Kyowa Kirin Biologics announced the European Commission (EC) has granted marketing authorization for Hulio, a biosimilar to AbbVie's Humira (adalimumab), for all indications.
Avita Medical received notification of the initial FDA review of the Pre-EUA (Emergency Use Authorization) submission to allow the emergency deployment of its ReCell device for a mass casualty event involving burn injuries.